|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.390 USD | +0.84% |
|
-0.62% | +33.06% |
| 13/05 | Protalix BioTherapeutics, Inc., Q1 2026 Earnings Call, May 13, 2026 | |
| 13/05 | Protalix BioTherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Protein and Genome Sequence Products | ||||||||||
Biotechnology (Startups) | 3.84Cr | 4.76Cr | 6.55Cr | 5.34Cr | 5.27Cr | |||||
Total Assets | 7.37Cr | 5.58Cr | 8.44Cr | 7.34Cr | 8.23Cr | |||||
Interest Expense | -62.94L | -25.29L | -31.8L | -10.62L | -11.91L | |||||
Income Tax Expense | - | 5L | 3L | 12.22L | 10L | |||||
CAPEX | -14.59L | -6L | -11.49L | -12.82L | -16.38L | |||||
EBT | -2.76Cr | -1.44Cr | 85.66L | 41.54L | -56.08L | |||||
Gross Profit | - | - | - | - | - | |||||
D&A | 11.18L | 10.86L | 11.91L | 13.04L | 14.65L | |||||
Operating Income | -2.05Cr | -1.3Cr | 1.05Cr | 39.17L | -55L | |||||
Net Income | -2.76Cr | -1.49Cr | 83.12L | 29.32L | -66.04L |
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Israel | - | - | - | - | - | |||||
Interest Expense | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
Total Assets | - | - | - | - | - | |||||
CAPEX | - | - | - | - | - | |||||
Gross Profit | - | - | - | - | - | |||||
Net Income | - | - | - | - | - | |||||
EBT | - | - | - | - | - | |||||
Operating Income | - | - | - | - | - |
- Stock Market
- Stocks
- PLX Stock
- Financials Protalix BioTherapeutics, Inc.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
